Abstract
Objectives
To investigate the value of CT spectral imaging in differentiating hepatocellular carcinoma (HCC) from focal nodular hyperplasia (FNH) during the arterial phase (AP) and portal venous phase (PP).
Methods
Fifty-eight patients with 42 HCCs and 16 FNHs underwent spectral CT during AP and PP. The lesion–liver contrast-to-noise ratio (CNR) at different energy levels, normalised iodine concentrations (NIC) and the lesion–normal parenchyma iodine concentration ratio (LNR) were calculated. The two-sample t test compared quantitative parameters. Two readers qualitatively assessed lesion types according to imaging features. Sensitivity and specificity of the qualitative and quantitative studies were compared.
Results
In general, CNRs at low energy levels (40–70 keV) were higher than those at high energy levels (80–140 keV). NICs and LNRs for HCC differed significantly from those of FNH: mean NICs were 0.25 mg/mL ± 0.08 versus 0.42 mg/mL ± 0.12 in AP and 0.52 mg/mL ± 0.14 versus 0.86 mg/mL ± 0.18 in PP. Mean LNRs were 2.97 ± 0.50 versus 6.15 ± 0.62 in AP and 0.99 ± 0.12 versus 1.22 ± 0.26 in PP. NICs and LNRs for HCC were lower than those of FNH. LNR in AP had the highest sensitivity and specificity in differentiating HCC from FNH.
Conclusions
CT spectral imaging may help to increase detectability of lesions and accuracy of differentiating HCC from FNH.
Key Points
• CT spectral imaging may help to detect hepatocellular carcinoma (HCC).
• CT spectral imaging may help differentiate HCC from focal nodular hyperplasia.
• Quantitative analysis of iodine concentration provides greater diagnostic confidence.
• Treatment can be given with greater confidence.
Similar content being viewed by others
Abbreviations
- AP:
-
arterial phase
- CNR:
-
contrast-to-noise ratio
- FNH:
-
focal nodular hyperplasia
- GSI:
-
Gemstone Spectral Imaging
- HCC:
-
hepatocellular carcinoma
- LNR:
-
lesion–normal parenchyma iodine concentration ratio
- NIC:
-
normalised iodine concentration
- PP:
-
portal venous phase
References
Schima W, Baron R (2010) Focal liver lesions. In: Hodler J, Von Schulthess GK, Zollikofer Ch L (eds) Diseases of the abdomen and pelvis 2010–2013: diagnostic imaging and interventional techniques, vol XIV. Springer, Milan, pp 63–74
Hussain SM, Terkivatan T, Zondervan PE et al (2001) Focal nodular hyperplasia: findings at state-of-the-art MR imaging, US, CT, and pathologic analysis. Radiographics 24:3–17
Ruppert-Kohlmayr AJ, Uggowitzer MM, Kugler C, Zebedin D, Schaffler G, Ruppert GS (2001) Focal nodular hyperplasia and hepatocellular adenoma of the liver: differentiation with multiphasic helical CT. Am J Roentgenol 176:1493–1498
van den Esschert JW, van Gulik TM, Phoa SSKS (2010) Imaging modalities for focal nodular hyperplasia and hepatocellular adenoma. Dig Surg 27:46–55
Savellano DH, Köstler H, Baus S et al (2004) Assessment of sequential enhancement patterns of focal nodular hyperplasia and hepatocellular carcinoma on mangafodipir trisodium enhanced MR imaging. Investig Radiol 39:305–312
Langrehr J, Pfitzmann R, Hermann M et al (2006) Hepatocellular carcinoma in association with hepatic focal nodular hyperplasia. Acta Radiologica 47:340–344
Lin XZ, Wu ZY, Tao R et al (2012) Dual energy spectral CT imaging of insulinoma–value in preoperative diagnosis compared with conventional multi-detector CT. Eur J Radiol 81:2487–2494
Lv P, Lin XZ, Li J, Li W, Chen K (2011) Differentiation of small hepatic hemangioma from small hepatocellular carcinoma: recently introduced spectral CT method. Radiology 259:720–729
Geyer LL, Scherr M, Körner M et al (2011) Imaging of acute pulmonary embolism using a dual energy CT system with rapid kVp switching: initial results. Eur J Radiol. doi:10.1016/j.ejrad.2011.02.043
Lv P, Lin XZ, Chen K, Gao J (2012) Spectral CT in patients with small HCC: investigation of image quality and diagnostic accuracy. Eur Radiol 22:2117–2124
Rutt BK, Cunningham IA, Fenster A (1983) Selective iodine imaging using lanthanum K fluorescence. Med Phys 10:801–808
Uggowitzer M, Kugler C, Gröll R et al (1998) Sonographic evaluation of focal nodular hyperplasia (FNH) of the liver with a transpulmonary galactose-based contrast-agent (Levovist). Br J Radiol 71:1026–1032
Uggowitzer M, Kugler C, Machan L et al (1997) Power Doppler imaging and evaluation of the resistive index in focal nodular hyperplasia of the liver. Abdom Imaging 22:268–273
Asayama Y, Yoshimitsu K, Nishihara Y et al (2008) Arterial blood supply of hepatocellular carcinoma and histologic grading: radiologic-pathologic correlation. AJR Am J Roentgenol 190:W28–W34
Hayashi M, Matsui O, Ueda K et al (1999) Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: evaluation by CT during intraarterial injection of contrast medium. AJR Am J Roentgenol 172:969–976
Matsui O (2004) Imaging of multistep human hepatocarcinogenesis by CT during intra-arterial contrast injection. Intervirology 47:271–276
Yoshikawa J, Matsui O, Takashima T et al (1988) Fatty metamorphosis in hepatocellular carcinoma: radiologic features in 10 cases. AJR Am J Roentgenol 151:717–720
Martin J, Sentis M, Zidan A et al (1995) Fatty metamorphosis of hepatocellular carcinoma: detection with chemical shift gradient-echo MR imaging. Radiology 195:125–130
Kutami R, Nakashima Y, Nakashima O, Shiota K, Kojiro M (2000) Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. J Hepatol 33:282–289
Acknowledgements
Our work has been supported by the National Natural Science Foundation of China (81071281) and the Science and Technology Commission of Shanghai Municipality (10411953000).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yu, Y., Lin, X., Chen, K. et al. Hepatocellular carcinoma and focal nodular hyperplasia of the liver: differentiation with CT spectral imaging. Eur Radiol 23, 1660–1668 (2013). https://doi.org/10.1007/s00330-012-2747-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-012-2747-0